THMP Moving Forward Together Partnership
The Texas HIV Medication Program (THMP) provides medications for the treatment of HIV and its related complications for low-income Texans. To qualify for medications, potential clients who meet eligibility criteria complete an application for assistance. Once approved, a client receives medications at an assigned pharmacy in their community.
To learn more about the THMP and find out if you are eligible, see the
Frequently Asked Questions. You can apply for the program by downloading and completing the
client application. Be sure and review the specific “application instructions” when completing the application. The application and its instructions are located on the
THMP document page. If you have more questions or need assistance completing your application, call the THMP toll free at 1-800-255-1090.
The THMP is the official AIDS Drug Assistance Program (ADAP) for the State of Texas. The THMP has been in existence since 1987 and provides medications approved by the Food and Drug Administration (FDA) for the treatment of illnesses caused by the human immunodeficiency virus (HIV) and other opportunistic infections in HIV-infected individuals as prescribed by their doctor. THMP also operates the Texas HIV State Pharmaceutical Assistance Program (SPAP) which helps HIV-positive individuals that do not qualify for the full Low-Income Subsidy (extra help) with their out-of-pocket costs associated with Medicare Part D prescription drug plans, including co-payments, deductibles, coinsurance, and during the coverage gap (the "donut hole").
THMP Proposed Rules to be Posted for Public Comment Through July 11
Proposed rules for the Texas HIV Medication Program (THMP) were presented at the Health and Human Services Commission (HHSC) Executive Council on Thursday, May 19, 2022. The rule amends the Texas Administrative Code, Title 25, Chapter 98 which governs the Department of State Health Services THMP rules, including the AIDS Drug Assistance Program, State Pharmacy Assistance Program, and Texas Insurance Assistance Program. Proposed rules are posted in the Texas Register for public comment. This public comment period will end on Monday, July 11, 2022. Proposed rules: Written comments on the proposal may be submitted to the TB/HIV/STD Section, P.O. Box 149347, Mail Code 1873, Austin, Texas 78714-9347; comments may be hand-delivered to the TB/HIV/STD Section at 201 W. Howard Lane, Austin, Texas, or emailed to HIVSTD@dshs.texas.gov.
To be considered, comments must be submitted no later than 31 days after the date of this issue of the Texas Register. Comments must be: - postmarked or shipped before the last day of the comment period;
- hand-delivered before 5:00 p.m. on the last working day of the comment period; or
- emailed before midnight on the last day of the comment period.
If the last day to submit comments falls on a holiday, comments must be postmarked, shipped, or emailed before midnight on the following business day to be accepted. When faxing or emailing comments, please indicate "Comments on Proposed Rule 21R050" in the subject line.
|
New Dosages of Three Medications Used To Treat HIV in Infants and Children Have Been Approved for Addition to the THMP Formulary
New dosages of three medications used to treat HIV in infants and children have been approved by the Department of State Health Services (DSHS) Commissioner of Health for addition to the Texas HIV Medication Program (THMP) AIDS Drug Assistance Program (ADAP) Formulary:
- Tivicay PD (dolutegravir) 25 mg
- Isentress (raltegravir) 25 mg
- low-dose Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg)
DSHS was able to estimate the fiscal impact of this change with reasonable certainty based on current data related to pediatric client loads and medications usage. The estimated fiscal impact of this change is minimal, with the possibility of a resulting positive fiscal impact when compared with maintaining only the current pediatric options. Consequently, DSHS is able to support these additions within existing monies and has approved adding these pediatric medications to the formulary.
The
THMP formulary (PDF) has been updated.
Please submit a new THMP
Medical Certification Form (MCF) for any infants and children in need of these new medication doses.
Thanks to the Medication Advisory Committee for recommending these changes.
|
Formulary Addition
A medication has been added to the THMP Formulary:
- Rukobia (fostemsavir tromethamine), 600 mg tablets, #60 per bottle
The Medical Certification Form and THMP Formulary have been updated. Both can be found on the
THMP documents page. |
Program applications, guidelines and formulary listings are available on the THMP document page.
|
|
THMP Eligibility Flyer (PDF)
THMP Eligibility Flyer (Spanish) (PDF)
THMP Email Lists
Sign up to one or more email lists below today to receive timely and relevant news from THMP: |
THMP News
Less frequent updates with news about significant events for the THMP program.
Subscribe to THMP News |
THMP Participating Pharmacies
Updates of interest to THMP participating pharmacies.
Subscribe to THMP Participating Pharmacies |
THMP Eligibility
Information for ADAP Enrollment Workers and others who assist clients in THMP application submission and their supervisors.
Subscribe to THMP Eligibility | |